Nucleome Therapeutics, a leading biotech company in the United Kingdom, is garnering attention in the realm of genetic research due to their innovative work on autoimmune diseases. The company has recently acquired a cutting-edge autoclave from LTE Scientific to support their groundbreaking studies. This decision is part of Nucleome’s expansion within the Oxford Science Park, where they have received substantial investments from esteemed organizations such as Oxford Science Enterprises, M Ventures, Pfizer Ventures, and Johnson & Johnson Innovation.
The upgrade to the LTE research-grade autoclave was essential for Nucleome’s transition from a shared facility at Oxford’s Old Road Campus to the Schrodinger Building at Oxford Science Park. The reliable autoclave was necessary to facilitate their advanced genetic research and LTE Scientific, a prominent UK autoclave manufacturer, was the natural choice for the project.
Paul Brackstone, Nucleome’s Director of Facilities, led the project in collaboration with LTE’s Sales Manager, Anthony Campbell-Carr. Paul’s meticulous attention to detail in specifying the waste disposal requirements, along with Anthony’s expert oversight during the installation process, ensured a seamless transition. Despite logistical challenges such as the Schrodinger Building’s small lift, LTE disassembled the autoclave for transport and reassembled it on site. The Touchclave-LAB 200K model was chosen for its efficiency in steam sterilization and adaptability to Nucleome’s needs.
The acquisition of the autoclave has proven to be a game-changer for Nucleome, significantly enhancing their waste control, health and safety procedures, and overall time management. Paul has praised the device’s user-friendliness and efficiency, highlighting its ability to sterilize lab coats without causing damage, thereby reducing the need for commercial cleaning and harmful chemicals.
In addition to the exceptional performance of the autoclave, Nucleome has commended LTE Scientific for their comprehensive support, from initial site visits to installation and ongoing customer service. The company’s proactive approach, competitive pricing, and high-quality equipment have played a pivotal role in the success of the project. Paul specifically praised LTE’s prompt response to any issues and their invaluable guidance, demonstrating their unwavering commitment to customer satisfaction.
The collaboration between Nucleome Therapeutics and LTE Scientific exemplifies the power of effective teamwork and the delivery of high-quality services. The integration of the Touchclave-LAB 200K autoclave into Nucleome’s pioneering research underscores LTE’s dedication to supporting advanced laboratory needs. For tailored solutions and equipment servicing, contacting LTE Scientific is the recommended course of action.
For those seeking further insights, the Digital Edition of Lab Asia 31.2, April 2024, offers valuable articles on chromatography and high-precision liquid flow processes, highlighting cutting-edge developments in the field. Furthermore, upcoming industry events in cities such as Anaheim, Frankfurt, Bangkok, Dusseldorf, and London provide professionals with an excellent opportunity to connect, learn, and stay abreast of the latest trends and advancements in the field.